Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...

Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer ...

According to Amanda, both children have faced challenges in adapting. Peyton is still grappling with the loss of another ...

Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.

But a team of researchers led by Kishore Guda, associate professor at the Digestive Health Research Institute at the Case Western Reserve School of Medicine, found a special class of ribonucleic acid ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...

In participants with a PD-L1 Tumor Area Positivity of at least ... Tevimbra is also indicated for esophageal cancer as monotherapy in adults with unresectable or metastatic ESCC after prior ...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

A man discovered that he has stage four cancer, and an estimated 12 months to live, all because he struggled to eat a bacon ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

Osamu Nishimura, a prominent Japanese wrestler, has died at 53 after battling esophageal cancer. Despite his late-stage diagnosis, he continued wrestl ...

BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent Tevimbra as a first-line therapy for certain patients with esophageal cancer as ...